Anixa Biosciences (ANIX) News Today $3.08 -0.05 (-1.60%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Anixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Down 28.9% in OctoberAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) saw a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 421,900 shares, a decline of 28.9% from the October 15th total of 593,700 shares. Based on an average daily volume of 75,800 shares, the short-interest ratio is presently 5.6 days. Approximately 1.4% of the company's shares are sold short.November 14 at 3:10 AM | marketbeat.comAnixa Biosciences Reports Promising Phase 1 Vaccine ResultsNovember 9, 2024 | markets.businessinsider.comAnixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual MeetingNovember 8, 2024 | prnewswire.comAnixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual MeetingNovember 6, 2024 | prnewswire.comAnixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024October 31, 2024 | prnewswire.comAnixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual MeetingOctober 28, 2024 | prnewswire.comAnixa Biosciences administers second CAR-T dose in ovarian cancer trialOctober 16, 2024 | finance.yahoo.comAnixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical TrialOctober 15, 2024 | prnewswire.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Down 8.9% in SeptemberAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) saw a large drop in short interest in September. As of September 30th, there was short interest totalling 627,200 shares, a drop of 8.9% from the September 15th total of 688,800 shares. Currently, 2.1% of the shares of the stock are short sold. Based on an average daily volume of 96,300 shares, the short-interest ratio is currently 6.5 days.October 15, 2024 | marketbeat.comAnixa Biosciences (NASDAQ:ANIX) Stock, Short Interest ReportOctober 13, 2024 | benzinga.comAnixa Biosciences (NASDAQ:ANIX) Stock Quotes, Forecast and News SummaryOctober 13, 2024 | benzinga.comPioneering Prevention: Comapny Creates Breast Cancer VaccineOctober 13, 2024 | msn.comAnixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical DevelopmentOctober 7, 2024 | prnewswire.comAnixa Biosciences Announces Submission of Protocol Amendment for CAR-T TrialSeptember 30, 2024 | prnewswire.comAnixa announces plans to launch Phase II breast cancer vaccine trialSeptember 25, 2024 | finance.yahoo.comAnixa Biosciences, Inc.: Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer VaccineSeptember 24, 2024 | finanznachrichten.deAnixa Shares Rise on Plans for Phase 2 Study of Breast Cancer VaccineSeptember 24, 2024 | marketwatch.comAnixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer VaccineSeptember 24, 2024 | prnewswire.comAnixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Ovarian Cancer Research Alliance's International Gynecologic Cancer ConferenceSeptember 18, 2024 | prnewswire.comBuy Rating Affirmed for Anixa Biosciences Amid Promising CAR-T Therapy Trials and Stable FinancialsSeptember 18, 2024 | markets.businessinsider.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Expected to Post FY2024 Earnings of ($0.42) Per ShareAnixa Biosciences, Inc. (NASDAQ:ANIX - Free Report) - HC Wainwright increased their FY2024 earnings per share (EPS) estimates for Anixa Biosciences in a research report issued on Monday, September 16th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($0.42) pSeptember 18, 2024 | marketbeat.comAnixa Biosciences (NASDAQ:ANIX) Earns Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $7.00 price objective on shares of Anixa Biosciences in a research note on Tuesday.September 17, 2024 | marketbeat.comAnixa Biosciences (NASDAQ:ANIX) Posts Earnings Results, Beats Estimates By $0.01 EPSAnixa Biosciences (NASDAQ:ANIX - Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.01.September 9, 2024 | marketbeat.comResearchers developing vaccine that could possibly prevent breast cancerSeptember 6, 2024 | msn.comAnixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research SymposiumSeptember 3, 2024 | prnewswire.comAnixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 26, 2024 | prnewswire.comEF Hutton sets stock target on Anixa Biosciences sharesAugust 9, 2024 | uk.investing.comAnixa Biosciences (NASDAQ:ANIX) Upgraded to "Strong-Buy" at EF Hutton Acquisition Co. IEF Hutton Acquisition Co. I raised Anixa Biosciences to a "strong-buy" rating in a research note on Wednesday.August 8, 2024 | marketbeat.comEF Hutton Initiates Coverage of Anixa Biosciences (ANIX) with Buy RecommendationAugust 7, 2024 | msn.comInsider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Purchases 21,646 Shares of StockAugust 2, 2024 | insidertrades.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. Acquires 21,646 SharesAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Lewis H. Titterton, Jr. acquired 21,646 shares of the company's stock in a transaction that occurred on Tuesday, July 30th. The stock was acquired at an average price of $3.06 per share, with a total value of $66,236.76. Following the acquisition, the director now owns 890,754 shares in the company, valued at $2,725,707.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.August 1, 2024 | marketbeat.comAnixa Biosciences And 3 Other Stocks Under $5 Insiders Are BuyingJuly 29, 2024 | msn.comAnixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Clinical Trial at the International Gynecologic Cancer Society 2024 Annual MeetingJuly 29, 2024 | prnewswire.comAnixa Biosciences director buys $15,450 worth of sharesJuly 28, 2024 | investing.comArnold M. Baskies Acquires 5,000 Shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) StockJuly 27, 2024 | insidertrades.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Director Buys $15,450.00 in StockAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Arnold M. Baskies bought 5,000 shares of the firm's stock in a transaction on Friday, July 26th. The stock was acquired at an average cost of $3.09 per share, with a total value of $15,450.00. Following the completion of the purchase, the director now owns 115,000 shares of the company's stock, valued at approximately $355,350. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.July 26, 2024 | marketbeat.comWe're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash WiselyJuly 26, 2024 | finance.yahoo.comBuy Rating Affirmed for Anixa Biosciences Amid Promising Cancer Therapy TrialsJuly 24, 2024 | markets.businessinsider.comHC Wainwright Reiterates Buy Rating for Anixa Biosciences (NASDAQ:ANIX)HC Wainwright reiterated a "buy" rating and set a $7.00 price objective on shares of Anixa Biosciences in a research note on Wednesday.July 24, 2024 | marketbeat.comCW39 New Breast Cancer Vaccine undergoing clinical TrialsJuly 23, 2024 | msn.comAnixa Biosciences, Inc.: Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T TherapyJuly 23, 2024 | finanznachrichten.deEXCLUSIVE: FDA Approves Anixa Biosciences' Individual Patient Trial Application For Ovarian Cancer CAR-T TherapyJuly 23, 2024 | uk.finance.yahoo.comAnixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T TherapyJuly 23, 2024 | prnewswire.comAnixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine TechnologyJuly 17, 2024 | prnewswire.comAnixa Biosciences Announces $5 Million Share Repurchase ProgramJuly 15, 2024 | prnewswire.comAnixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical TrialJune 24, 2024 | prnewswire.comInsider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Purchases 10,738 Shares of StockJune 11, 2024 | insidertrades.comLewis H. Titterton, Jr. Acquires 10,738 Shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) StockAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Lewis H. Titterton, Jr. bought 10,738 shares of the company's stock in a transaction on Friday, June 7th. The shares were acquired at an average price of $2.52 per share, with a total value of $27,059.76. Following the transaction, the director now directly owns 848,775 shares of the company's stock, valued at $2,138,913. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.June 10, 2024 | marketbeat.comHC Wainwright Trims Anixa Biosciences (NASDAQ:ANIX) Target Price to $7.00HC Wainwright dropped their price target on Anixa Biosciences from $12.00 to $7.00 and set a "buy" rating for the company in a report on Monday.June 10, 2024 | marketbeat.comInsider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) CFO Acquires 6,250 Shares of StockJune 8, 2024 | insidertrades.com Get Anixa Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Let’s be blunt (Ad)Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now ANIX Media Mentions By Week ANIX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANIX News Sentiment▼0.860.56▲Average Medical News Sentiment ANIX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANIX Articles This Week▼32▲ANIX Articles Average Week Get Anixa Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Enzo Biochem News Psychemedics News OpGen News C4 Therapeutics News Valneva News Organogenesis News 4D Molecular Therapeutics News MeiraGTx News Akebia Therapeutics News Canopy Growth News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ANIX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anixa Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANIX Stock Alerts